Bicycle Therapeutics (BCYC) Liabilities and Shareholders Equity (2018 - 2026)

Bicycle Therapeutics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $652.4 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 26.19% year-over-year to $652.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 billion (down 23.85% YoY) and the FY2025 annual result came in at $717.6 million, down 25.01% from the prior year.
• Liabilities and Shareholders Equity was $652.4 million for Q1 2026 at Bicycle Therapeutics, down from $717.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q2 2024 and bottomed at $410.6 million in Q4 2022.
• A 5-year average of $662.2 million and a median of $638.7 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 132.81% — and 2026, when it decreased 26.19%.
• Bicycle Therapeutics' Liabilities and Shareholders Equity stood at $410.6 million in 2022, then surged by 44.99% to $595.3 million in 2023, then soared by 60.73% to $956.9 million in 2024, then retreated by 25.01% to $717.6 million in 2025, then decreased by 9.09% to $652.4 million in 2026.
• Business Quant data shows BCYC's Liabilities and Shareholders Equity at $652.4 million in Q1 2026, $717.6 million in Q4 2025, and $764.0 million in Q3 2025.